Stablecoin Development Corp(NBY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.43 | Insider Own | 95.11% | Shs Outstand | 26.6M | Perf Week | - |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.3M | Perf Month | 43.38% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 5.34% | Short Float | 49.78% | Perf Quarter | -96.94% |
| Income | -0.01B | P/S | 14.11 | EPS this Y | - | Inst Trans | 77.46% | Short Ratio | 1.19 | Perf Half Y | -62.86% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -215.92% | Short Interest | 0.65M | Perf YTD | -93.09% |
| Book/sh | -2.23 | P/C | 17.29 | EPS past 3/5Y | 85.2% 68.77% | ROE | -587.58% | 52W High | -98.05% ($99.75) | Perf Year | 3.15% |
| Cash/sh | 0.11 | P/FCF | - | Sales past 3/5Y | - | ROIC | -395.68% | 52W Low | 75.68% ($1.11) | Perf 3Y | -99.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 95.81% | Gross Margin | 51.27% | Volatility(W/M) | 15.11% 17.86% | Perf 5Y | -99.95% |
| Dividend TTM | - | EV/Sales | 15.17 | Sales Y/Y TTM | -74.73% | Oper. Margin | -249.12% | ATR (14) | 0.72 | Perf 10Y | -99.98% |
| Dividend Ex-Date | 2025/9/30 | Quick Ratio | 1.98 | EPS Q/Q | 63.18% | Profit Margin | -285.09% | RSI (14) | 42.51 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.98 | Sales Q/Q | -78.66% | SMA20 | 40.19% ($1.39) | Beta | 0.46 | Target Price | $4.25 |
| Payout | - | Debt/Eq | 0.6 | Earnings | 2025/11/7 | SMA50 | -51.77% ($4.04) | Rel Volume | 0 | Prev Close | $1.95 |
| Employees | 4 | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | - | SMA200 | -78.08% ($8.9) | Avg Volume(3M) | 0.55M | Price | $1.95 |
| IPO | 2007/10/26 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🔬 Stablecoin Development (NBY) is a U.S. bio-healthcare venture company focused on the research and development of specialty pharmaceuticals for ophthalmic diseases, wound cleansing, and infection prevention, as well as specialized antimicrobial cleansing solutions, with proprietary technology for dry eye treatment and infection prevention.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
NBY has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,411. Peers typically go for $1,109.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
49.8% of the float is sold short.
Tap to view numbers
It ranks #433 of 596 in the industry
Based on market cap of $40M.
INMB#431 INmune Bio Inc $41M PER - 
GRDX#432 GridAI Technologies Corp $40M PER - NBY#433 Stablecoin Development Corp $40M PER - 
ATHE#433 Alterity Therapeutics Ltd ADR $40M PER - 
TIL#434 Instil Bio Inc $40M PER - 
FAQ
What kind of company is NBY?
NBY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NBY?
The market cap of NBY is approximately $40M, ranking 5,026 within its sector.
What is the 52-week high and low for NBY?
NBY has recorded a 52-week high of $99.75 and a low of $1.11.
